Clinical trial
Camrelizumab (PD-1 Antibody) Compared With Best Supportive Care After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (DIPPER)
NCT03427827 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Camrelizumab (PD-1 Antibody) Compared With Best Supportive Care After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (DIPPER)
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- July 2, 2018
- Completion date
- February 28, 2026
- Enrollment
- 450 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.